Mutations, Cancer and the Telomere Length Paradox

Trends in Cancer

Volumn 3, Issue 4, 2017, Pages 253-258

  Aviv, Abraham ^a   Anderson, James J ^b   Shay, Jerry W ^c,d  

^a University of Medicine and Dentistry of New Jersey Medical School   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

cancer; clones; evolution; mutation; stem cells; telomeres

Indexed keywords

CANCER GENETICS; CANCER RISK; CARCINOGENESIS; CLONAL VARIATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STEM CELL; TELOMERE LENGTH; GENETICS; MUTATION; NEOPLASM; TELOMERE;

HUMANS; MUTATION; NEOPLASMS; TELOMERE;

EID: 85017111149     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2017.02.005     Document Type: Review

References (48)

1. 1 Tomasetti, C., Vogelstein, B., Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347 (2015), 78–81.
2. 2 Wu, S., Substantial contribution of extrinsic risk factors to cancer development. Nature 529 (2016), 43–47.
3. 3 Shain, A.H., The genetic evolution of melanoma from precursor lesions. N. Engl. J. Med. 373 (2015), 1926–1936.
4. 4 Shay, J.W., Wright, W.E., Role of telomeres and telomerase in cancer. Semin. Cancer Biol. 21 (2011), 349–353.
5. 5 Maser, R.S., DePinho, R.A., Connecting chromosomes, crisis, and cancer. Science 297 (2002), 565–569.
6. 6 Savage, S.A., The long and short of telomeres and cancer association studies. J. Natl. Cancer Inst. 105 (2013), 448–449.
7. 7 Julin, B., Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J. Cancer 112 (2015), 769–776.
8. 8 Lynch, S.M., A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. Int. J. Cancer 133 (2013), 2672–2680.
9. 9 Iles, M.M., et al. The effect on melanoma risk of genes previously associated with telomere length. J. Natl. Cancer Inst., 106, 2014, dju267.
10. 10 Pellatt, A.J., Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study. Genes Chromosomes Cancer 52 (2013), 595–609.
11. 11 Seow, W.J., Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. Cancer Res. 74 (2014), 4090–4098.
12. 12 Machiela, M.J., Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. Int. J. Cancer 137 (2015), 311–319.
13. 13 Machiela, M.J., et al. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Hum. Mol. Genet. 25 (2016), 1663–1676.
14. 14 Haycock, P., et al. Association between telomere length and risk of cancer and non-neoplastic disease: a Mendelian randomization study. JAMA Oncology, 2017 (in press).
15. 15 Armitage, P., Doll, R., A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Brit J Cancer 11 (1957), 161–169.
16. 16 Armitage, P., Multistage models of carcinogenesis. Environ. Health Perspect. 63 (1985), 95–201.
17. 17 Nunney, L., Peto's paradox and the promise of comparative oncology. Philos. Trans. R Soc. Lond. B Biol Sci., 370, 2015, 1673.
18. 18 Sulak, M., et al. TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. Elife, 5, 2016, e11994.
19. 19 Abegglen, L.M., et al. Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans. JAMA 314 (2015), 1850–1860.
20. 20 Giono, L.E., Manfredi, J.J., The p53 tumor suppressor participates in multiple cell cycle checkpoints. J. Cell Physiol. 209 (2006), 13–20.
21. 21 Keane, M., Insights into the evolution of longevity from the bowhead whale genome. Cell Rep. 10 (2015), 112–122.
22. 22 Greaves, M., Darwinian medicine: a case for cancer. Nat. Rev. Cancer 7 (2007), 213–221.
23. 23 Gomes, N.M., Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 10 (2011), 761–768.
24. 24 Seluanov, A., Telomerase activity coevolves with body mass not lifespan. Aging Cell 6 (2007), 45–52.
25. 25 Slagboom, P.E., Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet. 55 (1994), 876–882.
26. 26 Broer, L., et al. Meta-analysis of telomere length in 19,713 subjects reveals high heritability, stronger maternal inheritance and a paternal age effect. Eur. J. Hum. Genet. 21 (2013), 1163–1168.
27. 27 Hjelmborg, J.B., The heritability of leucocyte telomere length dynamics. J. Med. Genet. 52 (2015), 297–302.
28. 28 Factor-Litvak, P., et al. Leukocyte telomere length in newborns: implications for the role of telomeres in human disease. Pediatrics, 137, 2016, e20153927.
29. 29 Codd, V., Identification of seven loci affecting mean telomere length and their association with disease. Nat. Genet. 45 (2013), 422–427.
30. 30 Haycock, P.C., Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ, 349, 2014, g4227.
31. 31 D'Mello, M.J., The Association between shortened leukocyte telomere length and cardio-metabolic outcomes: a systematic review and meta-analysis. Circ. Cardiovasc. Genet. 8 (2015), 82–90.
32. 32 Stone, R., Telomere length and the cancer-atherosclerosis trade-off. PLOS Genet., 12, 2016, e1006144.
33. 33 Hansen, M.E., Shorter telomere length in Europeans than in Africans due to polygenetic adaptation. Hum. Mol. Genet. 25 (2016), 2324–2330.
34. 34 Mangino, M., DCAF4, a novel gene associated with leucocyte telomere length. J. Med. Genet., 52, 2015 1571–1562.
35. 35 Greaves, M., When one mutation is all it takes. Cancer Cell 27 (2011), 433–434.
36. 36 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
37. 37 Rozhok, A.I., DeGregori, J., The evolution of lifespan and age-dependent cancer risk. Trends Cancer 2 (2016), 552–560.
38. 38 Nowell, P.C., The clonal evolution of tumor cell populations. Science 194 (1976), 23–28.
39. 39 Wong, M.S., Alternative splicing regulation of telomerase: a new paradigm?. Trends Genet. 30 (2014), 430–438.
40. 40 Hiyama, E., et al. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int. J. Oncol. 6 (1995), 13–16.
41. 41 de Lange, T., Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19 (2005), 2100–2110.
42. 42 Hirashima, K., Telomere length influences cancer cell differentiation in vivo. Mol. Cell Biol. 33 (2013), 2988–2995.
43. 43 Arbeev, K., et al. Decline in human cancer incidence rates at old ages: age-period-cohort considerations. Demographic Research 12 (2005), 273–300.
44. 44 Greaves, M., Does everyone develop covert cancer?. Nat. Rev. Cancer 14 (2014), 209–210.
45. 45 Chiba, K., et al. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife, 4, 2015, e07918.
46. 46 Armanios, M., Blackburn, E.H., The telomere syndromes. Nat. Rev. Genet. 13 (2012), 693–704.
47. 47 Verhulst, S., et al. Commentary: the reliability of telomere length measurements. Int. J. Epidemiol. 44 (2015), 1683–1686.
48. 48 Verhulst, S., et al. Response to: reliability and validity of telomere length measurements. Int. J. Epidemiol. 45 (2016), 1298–1301.